Vaccinia Virus Vector Bivalent Norovirus Vaccine
Viruses · 2025
DOI: 10.3390/v17020237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Yunbo Bai und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Norovirus, Viral Vaccines, Vaccinia virus, Caliciviridae Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
Norovirus is a major etiological agent of nonbacterial gastroenteritis around the world. Due to its in vitro culture complexity, high genome diversity, and the lack of cross-reactive immunity between genogroups, there is an unmet urgent need for polyvalent norovirus vaccines that provide broad-spectrum protection, and no vaccine has gained global approval to date. In this study, we constructed a bivalent norovirus vaccine, based on the highly attenuated poxvirus [strain VG9] vector, expressing the major capsid protein VP1 from genotypes GII.4 and GII.17. VG9-NOR exhibited a comparable replication ability to the authentic virus while preserving good safety. After the intramuscular and intranasal immunization of mice, VG9-NOR induced high IgG- and IgA-binding antibody (Ab) titers against GII.4 and GII.17, increased the secretion of GII.4 and GII.17-specific HGBA-blocking antibodies, and enhanced GII.17-specific mucosal immunity. Furthermore, VG9-NOR also induced a Th1-mediated cellular response. These results demonstrate that the polyvalent poxvirus vector vaccine expressing VP1 variants from different subtypes is able to elicit effective protection. Our study highlights the VG9 vector as a highly promising candidate for the development of polyvalent norovirus vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
- State Key Laboratory of Drug Regulatory Science, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, Beijing 102…
ORCID-Profile: Ziqi Cheng, Weijin Huang
Förderung
- National Key Research and Development Program
- National Key Research and Development Program of China
Zitieren
APA
Bai, Y., Wu, X., Shen, Y., Wang, L., Cheng, Z., Sun, Y., Wu, H., Zhang, Q., Sun, Z., He, C., Liao, B., Huang, W., & Xia, H. (2025). Vaccinia Virus Vector Bivalent Norovirus Vaccine. Viruses. https://doi.org/10.3390/v17020237
Vancouver
Bai Y, Wu X, Shen Y, Wang L, Cheng Z, Sun Y, et al. Vaccinia Virus Vector Bivalent Norovirus Vaccine. Viruses. 2025. doi:10.3390/v17020237
BibTeX
@article{Bai2025,
author = {Bai, Yunbo and Wu, Xi and Shen, Yanru and Wang, Liangliang and Cheng, Ziqi and Sun, Yeqing and Wu, Hao and Zhang, Qingfeng and Sun, Ziqi and He, Chenchen and Liao, Binfan and Huang, Weijin and Xia, Huanzhang},
title = {Vaccinia Virus Vector Bivalent Norovirus Vaccine},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17020237}
}
EUVIMED